Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of single-dose bevacizumab for ARDS in COVID-19
2020-001541-39Phase 2Terminated
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Crude mortality at 28 days. Started Apr 2020; status: terminated.
02
Drugs
bevacizumab
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001541-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001541-39.